{"DataElement":{"publicId":"6581908","version":"1","preferredName":"Liver Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for hepatocellular carcinoma and fibrolamellar carcinoma, using AJCC Ed. 8 criteria.","longName":"LIVR_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3179900","version":"1","preferredName":"Liver Cancer Group Stage","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"2834593v1.0:3377203v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2834593","version":"1","preferredName":"Hepatocellular Carcinoma","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","longName":"C3099","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62421A44-5466-782E-E040-BB89AD437669","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3377203","version":"1","preferredName":"Stage Grouping Stage","preferredDefinition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8A0D768-D501-B646-E040-BB89AD435C86","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-10","modifiedBy":"ONEDATA","dateModified":"2012-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F52449-32B9-E6AE-E040-BB89AD434DB8","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"TAYLORT","dateModified":"2018-12-19","changeDescription":"12/19/18 TT transferred ownership from NCIP to NCI Standards. Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6581882","version":"1","preferredName":"Hepatocellular Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of hepatocellular carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6581882v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IVB","valueDescription":"Stage IVB Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581889","version":"1","preferredName":"Stage IVB Hepatocellular Carcinoma AJCC v8","longName":"6581889","preferredDefinition":"Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Hepatocellular Carcinoma AJCC v8","conceptCode":"C134525","definition":"Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E8B0-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E8C9-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581891","version":"1","preferredName":"Stage IVA Hepatocellular Carcinoma AJCC v8","longName":"6581891","preferredDefinition":"Stage IVA includes: Any T, N1, M0. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Hepatocellular Carcinoma AJCC v8","conceptCode":"C134524","definition":"Stage IVA includes: Any T, N1, M0. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E8D6-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E8EF-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581893","version":"1","preferredName":"Stage IIIB Hepatocellular Carcinoma AJCC v8","longName":"6581893","preferredDefinition":"Stage IIIB includes: T4, N0, M0. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Hepatocellular Carcinoma AJCC v8","conceptCode":"C134522","definition":"Stage IIIB includes: T4, N0, M0. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E8FC-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E915-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581895","version":"1","preferredName":"Stage IIIA Hepatocellular Carcinoma AJCC v8","longName":"6581895","preferredDefinition":"Stage IIIA includes: T3, N0, M0. T3: Multiple tumors, at least one of which is larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Hepatocellular Carcinoma AJCC v8","conceptCode":"C134521","definition":"Stage IIIA includes: T3, N0, M0. T3: Multiple tumors, at least one of which is larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E922-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E93B-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581897","version":"1","preferredName":"Stage II Hepatocellular Carcinoma AJCC v8","longName":"6581897","preferredDefinition":"Stage II includes: T2, N0, M0. T2: Solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Hepatocellular Carcinoma AJCC v8","conceptCode":"C134519","definition":"Stage II includes: T2, N0, M0. T2: Solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E948-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E961-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581899","version":"1","preferredName":"Stage IB Hepatocellular Carcinoma AJCC v8","longName":"6581899","preferredDefinition":"Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Hepatocellular Carcinoma AJCC v8","conceptCode":"C134518","definition":"Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E96E-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E987-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Hepatocellular Carcinoma AJCC v8","ValueMeaning":{"publicId":"6581901","version":"1","preferredName":"Stage IA Hepatocellular Carcinoma AJCC v8","longName":"6581901","preferredDefinition":"Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 2 cm.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Hepatocellular Carcinoma AJCC v8","conceptCode":"C134517","definition":"Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 2 cm.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E994-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5FFF84-E9AD-61CF-E053-F662850A4AF2","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6581881","version":"1","preferredName":"Hepatocellular Carcinoma by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of hepatocellular carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C134515:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma by AJCC v8 Stage","conceptCode":"C134515","definition":"A term that refers to the staging of hepatocellular carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5FFF84-E883-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C5FFF84-E894-61CF-E053-F662850A4AF2","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-20-19 released per MC.; 12/6/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000438","version":"1","longName":"Liver","context":"NCI Standards"},{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779541","version":"1","longName":"LIHC Baseline","context":"OCCPR"}]}],"AlternateNames":[{"name":"OCCPR","type":"USED_BY","context":"OCCPR"}],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"},{"name":"CPTAC-BSLN-1","type":"Alternate Question Text","description":"Tumor Stage (Pathologic)","url":null,"context":"OCCPR"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C609E85-3E64-4874-E053-F662850A8C5A","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeDescription":"8-30-19 TMT released per MC.; 12/6/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}